Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Cisplatin in advanced epithelial ovarian cancer
NCT00191334Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in Epithelial Ovarian Cancer (EOC), sponsored by Eli Lilly and Company. Primary endpoint: Best Overall Tumor Response. Started Dec 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT00191334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191334.